Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges
A concise report featuring insights from the prominent thought leaders of Biologics 2024
Top R&D Stories of 2023
Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
.jpg)
Antibody & Protein Engineering
Q&A with Silvia Crescioli, Business Intelligence Creator, The Antibody Society
We catch up with Silvia Crescioli from The Antibody Society to unpack the latest trends and technologies fuelling progress in antibody therapeutic development.
NextGen Therapeutics
Historic Islet Cell Transplant Offers Hope for a Permanent Cure for Type 1 Diabetes
A study led by Professor Deng Hongkui at Peking University successfully treated a type 1 diabetes patient by transplanting insulin-producing islet cells derived from the patient's reprogrammed stem cells.
NextGen Therapeutics
Lonza and Vertex Pen Long Term Supply Deal for CASGEVY
Lonza will provide scientific, regulatory and manufacturing capabilities to Vertex, as well as use of their global manufacturing network.
NextGen Therapeutics
Tackling Tumours from Within: Tumour Reprogramming Offers Hope in Cancer Immunotherapy
A novel gene therapy developed by Asgard Therapeutics and Lund University reprograms tumour cells into cancer-fighting immune cells.
Antibody & Protein Engineering
Absci to Collaborate with the Memorial Sloan Kettering Cancer Center to Develop Biologics using AI
The two organisations will work side by side on up to six programmes which will develop new cancer drug candidates using AI.
Peptide Chemistry
RSC 'Emerging Technologies' Award Goes to Solid Phase Peptide Synthesis Group
The novel peptide synthesis protocol allows the synthesis of multiple peptide fragments on a single bead.
Regulatory
FDA Fast Track ADC for Patients with Triple Negative Breast Cancer
The fast track designation means that the clinical development and regulatory milestones of the drug candidate are likely to progress much faster.
NextGen Therapeutics
GSK Buys CureVac's mRNA Vaccine Business Providing Welcome Cash Injection
CureVac will continue to build its R&D pipeline while allowing GSK to develop and commercialise a handful of its prophylactic mRNA vaccines.
Bioanalysis
2002 Nobel Prize for Chemistry: Kurt Wüthrich, Using NMR to Determine the 3D Structure of Proteins
Kurt Wüthrich, joint winner of the 2002 Nobel Prize for Chemistry, contributed to the use of NMR to discover the 3D structure of proteins using sequential assignment and mathematical techniques.
Bioanalysis
Looking Back on the 2002 Nobel Prize for Chemistry: Mass Spectrometry for the Analysis of Proteins
2002's Nobel Prize for Chemistry recognised the translation of mass spectrometry to large molecules which has been instrumental in unlocking the proteome toward new therapies.
H5N1 Bird Flu Outbreaks: Effect on Vaccines
H5N1 outbreaks in the US have mobilised pandemic preparedness mechanisms with stockpiling of avian flu vaccines.
"World's First" IND Approval for Epstein-Barr mRNA Cancer Vaccine
Epstein-Barr virus has been highly linked to over ten forms of cancer. This wide range of malignant implications means an expanded variety of target indications for the vaccine.